You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline

Medicines mismanagement

By Mindo - 21st Sep 2017 | 8 views

Despite the promise to fund nine new innovative medicines, across the areas of oncology, cardiology, rheumatology and dermatology that were approved some months ago, patients are still waiting.

This is despite the Department of Health and HSE playing a slow game of ‘pass the parcel’ in relation to who would make the decision to fund these undeniably expensive medicines. However, after rigorous assessment processes and the Department firmly stating that the ultimate decision and the necessary budget lay with the HSE, patients and clinicians are still in limbo. The HSE is also under fire for refusing to fund a breakthrough treatment for Duchenne muscular dystrophy that is available to patients in Northern Ireland and a treatment for a rare form of emphysema, which has been available on a compassionate basis to Irish patients for many years but is due to be stopped.

From being a country where patients had good access to new medicines, Ireland is falling down the list compared to our counterparts in Europe, according to the Irish Pharmaceutical Healthcare Association (IPHA). The situation for cancer medicines is particularly negative. In 2016, only 20 per cent of new cancer medicines launched internationally in 2014-15 were available to patients in Ireland. Ten years ago, it was a very different case.

While the cost of new innovative medicines is a significant challenge for our health budget, when decisions are made to fund treatments, surely it is not too much to ask that they are then promptly made available to patients, instead of dragging-out the inevitable to try and balance this year’s books?

 And in another worrying development, as Niamh Cahill investigates in this issue, there have been reports of hospital inpatients being asked to source high-tech medications, such as monoclonal antibodies, prescribed by hospital clinicians, from their community pharmacies while they remain in hospital — in an apparent attempt to move the cost from the hospital budget to the community drugs budget.

GPs and pharmacists are concerned about the emerging practice, which has health and safety repercussions as well as being stressful and confusing for patients.

The HSE must investigate these reports and put a stop to such behaviour.

<p class=”HeadB25MIstyles”>While it is imperative that we obtain the best possible value for money when negotiating on all medicines, and that we fund treatments that have a proven benefit, it is clear that the current system and behaviour of the purse masters is not acceptable. It is completely unfair to affected patients and to frustrated clinicians who have been able to see first-hand the positive results from local clinical trials and then have to deny needy patients the best option for treatment, as approved medications are caught in an endless limbo.

Leave a Reply

Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read